^
Association details:
| Biomarker: | KRAS Q61H |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | RMC-0708 (KRAS Q61H inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RM-046, a first-in-class, mutant-selective, and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target
Published date:
03/15/2023
Excerpt:
Daily oral administration of RM-046 demonstrated dose-dependent anti-tumor activity and drove deep tumor regressions across several preclinical xenograft models of human KRASQ61H tumors, including NSCLC and PDAC.
